搜索
NanoViricides Inc
NNVC添加自选
1.480USD
-0.255-14.66%
收盘 05/15, 16:00（美东）报价延迟15分钟
32.04M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-14.66%
5天
-4.52%
1月
+27.59%
6月
+4.23%
今年开始到现在
+30.97%
1年
+4.96%
TradingKey NanoViricides Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
NanoViricides Inc当前公司基本面数据相对谨慎，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名162/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价6.00。中期看，股价处于上升通道。近一个月，市场表现很强，技术面评分较高，但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
NanoViricides Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
NanoViricides Inc亮点
亮点风险
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.
估值低估
公司最新PE估值-3.41，处于3年历史低位
机构加仓
最新机构持股3.93M股，环比增加34.23%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值173.40K
活跃度增加
近期活跃度增加，过去20天平均换手率0.34
分析师目标
根据
1
位分析师
买入
评级
6.000
目标均价
+248.84%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
NanoViricides Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
NanoViricides Inc简介
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.
公司代码NNVC
公司NanoViricides Inc
CEODiwan (Anil)
网址https://www.nanoviricides.com/
相关品种
